Safety and efficacy of idalopirdine, a 5-HT 6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial
Authors:
- 1 November 2014
- journal article
- research article
- Published by Elsevier in The Lancet Neurology
- Vol. 13 (11) , 1092-1099
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Role of Serotonin in Alzheimerʼs DiseaseCNS Drugs, 2011
- The Central Role of 5-HT6 Receptors in Modulating Brain Neurochemistry2011
- SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled studyInternational Journal of Geriatric Psychiatry, 2010
- Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in ratsInternational Journal of Neuropsychopharmacology, 2010
- MMRM vs. LOCF: A Comprehensive Comparison Based on Simulation Study and 25 NDA DatasetsJournal of Biopharmaceutical Statistics, 2009
- 5-HT6 Receptor Antagonists as Novel Cognitive Enhancing Agents for Alzheimer's DiseaseNeurotherapeutics, 2008
- An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs DiseaseAlzheimer Disease & Associated Disorders, 1997
- Validity and Reliability of the Alzheimerʼs Disease Cooperative Study-Clinical Global Impression of ChangeAlzheimer Disease & Associated Disorders, 1997
- The Neuropsychiatric InventoryNeurology, 1994
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984